U.S. market Closed. Opens in 1 day 10 hours 46 minutes

PLUR | Pluri Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 4.44 - 4.98
52 Week Range 3.76 - 8.48
Beta 1.12
Implied Volatility 558.91%
IV Rank 87.36%
Day's Volume 13,498
Average Volume 26,322
Shares Outstanding 5,558,660
Market Cap 26,792,741
Sector Healthcare
Industry Biotechnology
IPO Date 2003-06-30
Valuation
Profitability
Growth
Health
P/E Ratio -1.17
Forward P/E Ratio N/A
EPS -4.11
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 106
Country Israel
Website PLUR
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
*Chart delayed
Analyzing fundamentals for PLUR we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see PLUR Fundamentals page.

Watching at PLUR technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on PLUR Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙